Get the Stockscreener App
32.42
5.95%
1.82
Pre-market:
33.01
0.59
+1.82%
Forte Biosciences Inc stock is traded at $32.42, with a volume of 292.30K.
It is up +5.95% in the last 24 hours and up +21.24% over the past month.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
See More
Previous Close:
$30.60
Open:
$30.61
24h Volume:
292.30K
Relative Volume:
1.05
Market Cap:
$450.17M
Revenue:
-
Net Income/Loss:
$-69.38M
P/E Ratio:
-6.1877
EPS:
-5.2394
Net Cash Flow:
$-51.00M
1W Performance:
+23.88%
1M Performance:
+21.24%
6M Performance:
+133.41%
1Y Performance:
+479.96%
1-Day Range:
$30.61
$34.60
1-Week Range:
$25.09
$35.80
52-Week Range:
$4.90
$35.80
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
32.42 | 487.25M | 0 | -69.38M | -51.00M | -5.2394 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Evercore ISI | Outperform |
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Forte Biosciences Announces $150 Million Public Offering of Common Stock - Global Legal Chronicle
Quarterly Recap: Will Forte Biosciences Inc outperform small cap indexes2026 Volume Leaders & Trade Opportunity Analysis - baoquankhu1.vn
Weekly Recap: Is Forte Biosciences Inc being accumulated by smart money2026 Analyst Calls & Advanced Technical Signal Analysis - baoquankhu1.vn
Forte Biosciences: 2026 Is Major Inflection Point For FB102 (NASDAQ:FBRX) - Seeking Alpha
Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts - Seeking Alpha
BlackBerry Posts Upbeat Q4 Results, Joins STZ, MRVL And Other Big Stocks Moving Higher On Thursday - Sahm
VIX Spike: Is Forte Biosciences Inc part of any major index2026 Pullback Review & Weekly Return Optimization Alerts - baoquankhu1.vn
Bull Bear: Does Forte Biosciences Inc have pricing powerOptions Play & Community Verified Trade Signals - baoquankhu1.vn
Forte Biosciences Boosts Market Position with $150M Public Offering - timothysykes.com
Forte Biosciences (NASDAQ: FBRX) registers 5.71M shares at $26.27 - Stock Titan
TPG closes $18 billion take-private deal, publicly traded biotech to raise $150M - The Business Journals
Brookline Capital Markets Cuts Forte Biosciences FY2026 Earnings Forecast - National Today
Forte Biosciences Prices $150 Million Public Offering - TipRanks
Forte Biosciences Prices $150 Million Stock Offering at $26.27; Underwriting Led by Guggenheim - TradingView — Track All Markets
Forte Biosciences (NASDAQ: FBRX) prices $150M common stock sale - Stock Titan
Forte Biosciences prices 5.71M shares at $26.27 in $150M capital raise - MSN
Forte Biosciences Prices $150 Million Stock Offering - marketscreener.com
Wilson Sonsini Advises Forte Biosciences on $150 Million Public Offering - Wilson Sonsini
Forte Biosciences prices $150M stock offering at $26.27/share By Investing.com - Investing.com India
Forte Biosciences Announces Pricing of $150 Million Public Offering - Weekly Voice
Forte Biosciences prices $150M stock offering at $26.27/share - Investing.com
Forte Biosciences announces pricing of $150 million public offering - marketscreener.com
Forte Biosciences Announces Pricing Of $150 Million Public Offering - TradingView — Track All Markets
Forte Biosciences launches public stock offering By Investing.com - Investing.com South Africa
Forte Biosciences launches public stock offering - Investing.com
Forte Biosciences (FBRX) files prospectus supplement to sell common stock - Stock Titan
Forte Biosciences Announces Proposed Public Offering - marketscreener.com
Drug developer Forte launches stock sale to fund clinical research - Stock Titan
Forte Biosciences Inc stock: What investors need to know in biotech volatility - AD HOC NEWS
Buybacks Report: Will Forte Biosciences Inc announce a stock splitShare Buyback & Daily Entry Point Alerts - baoquankhu1.vn
Tech Rally: Is Forte Biosciences Inc trading at a discount2026 Pullbacks & Safe Entry Trade Reports - baoquankhu1.vn
Published on: 2026-04-05 11:22:35 - baoquankhu1.vn
Precision Trading with Forte Biosciences Inc. (FBRX) Risk Zones - Stock Traders Daily
Forte Biosciences and Pasithea Therapeutics Face Off in Financial Comparison - National Today
Forte Biosciences (NASDAQ: FBRX) CFO exercises RSUs, 134 shares withheld - Stock Titan
Forte Biosciences (FBRX) director boosts stake after RSU vesting - Stock Titan
Guggenheim reiterates Forte Biosciences stock rating ahead of data By Investing.com - Investing.com India
Guggenheim reiterates Forte Biosciences stock rating ahead of data - Investing.com
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX) - The Globe and Mail
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX) - MarketBeat
Forte Biosciences Reports 2025 Financial Results and Provides FB102 Clinical Development Updates for Celiac Disease, Vitiligo, and Alopecia Areata - Minichart
FB102 trials drive higher 2025 R&D at Forte Biosciences (NASDAQ: FBRX) - Stock Titan
Forte Biosciences (NASDAQ:FBRX) Announces Quarterly Earnings Results - MarketBeat
Forte Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Forte Biosciences (NASDAQ: FBRX) advances FB102 with positive celiac data and funds trials through equity raises - Stock Titan
Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Forte Biosciences, Inc. Announces 2025 Results and Provides Update - The Joplin Globe
Three FB102 disease readouts are due in 2026 after Forte spent $58M - Stock Titan
Reviewing Pasithea Therapeutics (NASDAQ:KTTA) and Forte Biosciences (NASDAQ:FBRX) - Defense World
FBRX Stock Price, Quote & Chart | FORTE BIOSCIENCES INC (NASDAQ:FBRX) - ChartMill
Forte Biosciences, Inc.: Fundamental Analysis and Financial Ratings | | US34962G2084 - MarketScreener
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):